Comparability of Osteoporosis Treatment Groups Among Female Medicare Beneficiaries in the United States
Authors' conclusion
According to comparability decision rules established a priori, patients initiating denosumab were comparable to those initiating zoledronic acid or alendronate, irrespective of prior osteoporosis treatment experience.
Study context
- Population
- Postmenopausal women (female Medicare beneficiaries) treated with osteoporosis medications, US CMS Chronic Condition Warehouse claims data (May 2010-December 2016)
- Exposure
- Denosumab vs zoledronic acid or oral bisphosphonates
- Outcome
- Comparability by a priori decision rules
Methodological detailspropensity-score matched 1:1, negative control outcomes
- Propensity-score matched 1:1
- Negative control outcomes
Main finding
As reported in the abstract
- Patients initiating denosumab were comparable to those initiating zoledronic acid or alendronate, irrespective of prior osteoporosis treatment experience
Observational data: associations, not effects.
Further findings
Cumulative incidence of the 7 negative control outcomes (NCOs), denosumab vs zoledronic acid, in new users, new switchers and historical fracture subgroup
- No meaningful differences observed
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Comparability of Osteoporosis Treatment Groups Among Female Medicare Beneficiaries in the United States. J Bone Miner Res. Published 23 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →